CA3172981A1 - Methode de traitement de troubles neurologiques a l'aide d'un entrainement de voie synaptique - Google Patents
Methode de traitement de troubles neurologiques a l'aide d'un entrainement de voie synaptique Download PDFInfo
- Publication number
- CA3172981A1 CA3172981A1 CA3172981A CA3172981A CA3172981A1 CA 3172981 A1 CA3172981 A1 CA 3172981A1 CA 3172981 A CA3172981 A CA 3172981A CA 3172981 A CA3172981 A CA 3172981A CA 3172981 A1 CA3172981 A1 CA 3172981A1
- Authority
- CA
- Canada
- Prior art keywords
- synaptic
- pathway
- brain
- depression
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000946 synaptic effect Effects 0.000 title claims abstract description 112
- 230000037361 pathway Effects 0.000 title claims abstract description 93
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000012549 training Methods 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title abstract description 47
- 208000012902 Nervous system disease Diseases 0.000 title description 3
- 208000025966 Neurological disease Diseases 0.000 title description 3
- 239000002831 pharmacologic agent Substances 0.000 claims abstract description 39
- 230000004936 stimulating effect Effects 0.000 claims abstract description 31
- 210000004556 brain Anatomy 0.000 claims abstract description 30
- 230000001149 cognitive effect Effects 0.000 claims abstract description 23
- 230000003213 activating effect Effects 0.000 claims abstract description 19
- 208000028173 post-traumatic stress disease Diseases 0.000 claims abstract description 17
- 208000007848 Alcoholism Diseases 0.000 claims description 21
- 201000007930 alcohol dependence Diseases 0.000 claims description 19
- 208000020925 Bipolar disease Diseases 0.000 claims description 13
- 230000000926 neurological effect Effects 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003400 hallucinatory effect Effects 0.000 claims description 2
- 238000011457 non-pharmacological treatment Methods 0.000 claims 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 abstract description 39
- 229960003299 ketamine Drugs 0.000 abstract description 39
- 230000000638 stimulation Effects 0.000 abstract description 30
- 208000024891 symptom Diseases 0.000 abstract description 25
- 206010026749 Mania Diseases 0.000 abstract description 13
- 230000001953 sensory effect Effects 0.000 abstract description 8
- 230000002349 favourable effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 24
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 12
- 210000001320 hippocampus Anatomy 0.000 description 11
- 230000004913 activation Effects 0.000 description 9
- 238000002483 medication Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000009225 cognitive behavioral therapy Methods 0.000 description 8
- 238000002635 electroconvulsive therapy Methods 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 238000001802 infusion Methods 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 6
- 210000000225 synapse Anatomy 0.000 description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011458 pharmacological treatment Methods 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 210000005215 presynaptic neuron Anatomy 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010010219 Compulsions Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 206010013470 Dissociative states Diseases 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 2
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003715 limbic system Anatomy 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
- 230000006611 pharmacological activation Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical group C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Natural products NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229940121743 Muscarinic receptor agonist Drugs 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- -1 aryl cyclohexylamine Chemical compound 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000010336 brain pathway Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229950002454 lysergide Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000008284 neuronal mechanism Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical group C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001337 psychedelic effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013522 vodka Nutrition 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Social Psychology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Sont divulguées des méthodes de traitement de la dépression, de la manie, du trouble du stress post-traumatique (PTSD) et de diverses autres affections neurologiques au moyen d'un entraînement de voie synaptique. Les méthodes d'entraînement de voie synaptique comprennent, en général, l'obtention d'un résultat de traitement favorable par activation d'une voie synaptique à l'aide d'un agent pharmacologique, tel que le traitement de symptômes réfractaires de la dépression par la kétamine, suite à la potentialisation du résultat favorable par stimulation répétée de la voie activée. La stimulation d'une voie synaptique peut être obtenue par des moyens intrinsèques, tels que l'activation de la fonction cognitive exercée, ou des moyens extrinsèques, tels que l'administration d'un stimulus sensoriel au patient, la mise en place d'une différence de tension potentielle à travers le cerveau ou une région cérébrale, ou en plaçant le cerveau ou une région cérébrale dans un champ magnétique.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/827,546 | 2020-03-23 | ||
| US16/827,546 US20200222656A1 (en) | 2016-10-18 | 2020-03-23 | Method for treatment of depression using synaptic pathway training |
| PCT/US2021/022517 WO2021194796A1 (fr) | 2020-03-23 | 2021-03-16 | Méthode de traitement de troubles neurologiques à l'aide d'un entraînement de voie synaptique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172981A1 true CA3172981A1 (fr) | 2021-09-30 |
Family
ID=77890584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172981A Pending CA3172981A1 (fr) | 2020-03-23 | 2021-03-16 | Methode de traitement de troubles neurologiques a l'aide d'un entrainement de voie synaptique |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4126199A4 (fr) |
| BR (1) | BR112022019234A2 (fr) |
| CA (1) | CA3172981A1 (fr) |
| IL (1) | IL296693A (fr) |
| MX (1) | MX2022011862A (fr) |
| WO (1) | WO2021194796A1 (fr) |
| ZA (1) | ZA202210356B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230202978A1 (en) | 2022-03-04 | 2023-06-29 | Reset Pharmaceuticals, Inc. | Co-crystal or salt |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9064036B2 (en) * | 2008-04-24 | 2015-06-23 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
| WO2016004396A1 (fr) * | 2014-07-02 | 2016-01-07 | Christopher Decharms | Technologies pour entraînement d'exercice cérébral |
| WO2016061320A2 (fr) * | 2014-10-15 | 2016-04-21 | Rowan University | Thérapie timber pour le trouble du stress post-traumatique |
| WO2017180589A1 (fr) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Dérivés de kétamine deutérés |
| US10596378B2 (en) * | 2016-10-18 | 2020-03-24 | Joseph Rustick | Method for treatment of depression using synaptic pathway training |
| US20200222656A1 (en) * | 2016-10-18 | 2020-07-16 | Joseph Rustick | Method for treatment of depression using synaptic pathway training |
| AU2019262197A1 (en) * | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
-
2021
- 2021-03-16 CA CA3172981A patent/CA3172981A1/fr active Pending
- 2021-03-16 EP EP21776197.2A patent/EP4126199A4/fr active Pending
- 2021-03-16 WO PCT/US2021/022517 patent/WO2021194796A1/fr unknown
- 2021-03-16 MX MX2022011862A patent/MX2022011862A/es unknown
- 2021-03-16 BR BR112022019234A patent/BR112022019234A2/pt unknown
- 2021-03-16 IL IL296693A patent/IL296693A/en unknown
-
2022
- 2022-09-19 ZA ZA2022/10356A patent/ZA202210356B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4126199A1 (fr) | 2023-02-08 |
| ZA202210356B (en) | 2023-02-22 |
| WO2021194796A1 (fr) | 2021-09-30 |
| BR112022019234A2 (pt) | 2022-11-08 |
| EP4126199A4 (fr) | 2024-04-10 |
| IL296693A (en) | 2022-11-01 |
| MX2022011862A (es) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230347101A1 (en) | Method for treatment of depression using synaptic pathway training | |
| US10596378B2 (en) | Method for treatment of depression using synaptic pathway training | |
| US10716950B2 (en) | Treatment of thalamocortical dysrhythmia | |
| US6391922B1 (en) | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders | |
| Koh et al. | Use of hyaluronidase as an adjuvant to ropivacaine to reduce axillary brachial plexus block onset time: a prospective, randomised controlled study | |
| CA3172981A1 (fr) | Methode de traitement de troubles neurologiques a l'aide d'un entrainement de voie synaptique | |
| Kreuzer et al. | A case report on red ear syndrome with tinnitus successfully treated with transcranial random noise stimulation | |
| Eleftheriou et al. | Deep temporal lobe stimulation in man | |
| RU2665629C1 (ru) | Способ лечения алкоголизма | |
| Bays-Muchmore et al. | Transient Ipsilateral Trigeminal Neuropathy After 10 Hz Left-Sided Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder: A Case Study | |
| RU2139110C1 (ru) | Способ комплексного лечения генерализованных болевых синдромов неорганического генеза | |
| Строкань et al. | The problem of phantom pain | |
| Alp | An Evaluation of the Depression Symptoms Level Using the Beck Depression Inventory Scale in Patients Receiving Acupuncture for Chronic Pain | |
| Lanius | Developmental Trauma, LENS and Neural Regulation: Brain and Body | |
| JP2008506630A (ja) | ゾルピデムの更なる治療的使用 | |
| Fink | Treatment and Prevention of Opiate Dependence | |
| WO2019172737A1 (fr) | Méthode de traitement d'encéphalopathie | |
| Brinkhaus | Acupuncture for Chronic Heart Failure | |
| Galea | Spinal cord injury and physical activity |